Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 2 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Altimmune, Inc.

Market implies +150.0%/yr vs model +2.0% · above model

Market implies -50.0%/yr vs model +50.0% · below model

ALX ONCOLOGY HOLDINGS INC

Alzamend Neuro, Inc.

Deeply overvalued

Model IV$155.98

Premium +52% Return to IV: -34.4%

Owner yield 3.0% 10-yr IRR 3.2% · moderate

Market implies +12.4%/yr vs model +8.2% · above model

Model IV$452.91

Discount 15% Return to IV: +17.4%

Owner yield 4.1% 10-yr IRR 9.0% · moderate

Market implies +6.4%/yr vs model +10.7% · below model

Autonomix Medical, Inc.

Amylyx Pharmaceuticals, Inc.

Market implies +44.6%/yr vs model +15.0% · above model

Amphastar Pharmaceuticals, Inc.

Deeply undervalued

Discount 44% Return to IV: +77.7%

Owner yield 12.9% 10-yr IRR 29.6% · grower

Market implies +1.3%/yr vs model +13.1% · below model

AMARIN CORP PLCUK

Market implies +39.2%/yr vs model +2.0% · above model

Amneal Pharmaceuticals, Inc.

Premium +17% Return to IV: -14.7%

Owner yield 4.5% 10-yr IRR 9.4% · moderate

Market implies +9.9%/yr vs model +9.7% · in line

AMERICAN SHARED HOSPITAL SERVICES

Deeply undervalued

Discount 89% Return to IV: +773.6%

Market implies -50.0%/yr vs model +12.4% · below model

ANAPTYSBIO, INC

Premium +16% Return to IV: -13.8%

Market implies -1.2%/yr vs model +38.8% · below model

ANGIODYNAMICS INC

Deeply overvalued

Premium +155% Return to IV: -60.8%

Market implies +11.8%/yr vs model +2.0% · above model

Anika Therapeutics, Inc.

Deeply overvalued

Premium +176% Return to IV: -63.8%

Market implies +10.6%/yr vs model +2.0% · above model

ANI PHARMACEUTICALS INC

Deeply undervalued

Model IV$369.54

Discount 79% Return to IV: +385.3%

Owner yield 6.8% 10-yr IRR 19.7% · grower

Market implies -2.7%/yr vs model +25.0% · below model

Anixa Biosciences Inc

Adlai Nortye Ltd.

Alto Neuroscience, Inc.

AN2 Therapeutics, Inc.

Annovis Bio, Inc.

Discount 8% Return to IV: +8.3%

Market implies -8.0%/yr vs model +10.2% · below model

Apogee Therapeutics, Inc.

Apollomics Inc.

Apollomics Inc.

Aptorum Group Ltd

Market implies +61.6%/yr vs model +15.0% · above model

Aprea Therapeutics, Inc.

ALPHA PRO TECH LTD

Discount 29% Return to IV: +39.9%

Owner yield 7.0% 10-yr IRR 13.7% · moderate

Market implies -0.5%/yr vs model +7.0% · below model

Apimeds Pharmaceuticals US, Inc.

Aptevo Therapeutics Inc.

Market implies -18.8%/yr vs model +15.0% · below model

Apyx Medical Corp

Market implies +29.3%/yr vs model +2.2% · above model

Aquestive Therapeutics, Inc.

Market implies +47.4%/yr vs model +2.0% · above model

Market implies -50.0%/yr vs model +3.7% · below model

Arcturus Therapeutics Holdings Inc.

Deeply undervalued

Discount 68% Return to IV: +216.5%

Market implies -19.0%/yr vs model +50.0% · below model

Ardent Health, Inc.

Deeply undervalued

Discount 72% Return to IV: +259.0%

Market implies -13.3%/yr vs model +8.1% · below model

Deeply undervalued

Discount 74% Return to IV: +281.9%

Market implies -22.2%/yr vs model +50.0% · below model

Armata Pharmaceuticals, Inc.

Arcutis Biotherapeutics, Inc.

Deeply overvalued

Premium +469% Return to IV: -82.4%

Market implies +24.3%/yr vs model +15.0% · above model

ARTELO BIOSCIENCES, INC.

Artiva Biotherapeutics, Inc.

Market implies +115.7%/yr vs model +15.0% · above model

Deeply undervalued

Discount 69% Return to IV: +217.7%

Market implies -20.4%/yr vs model +48.8% · below model

ARROWHEAD PHARMACEUTICALS, INC.

Deeply overvalued

Premium +195% Return to IV: -66.1%

Market implies +33.7%/yr vs model +25.0% · above model

Aspire Biopharma Holdings, Inc.

Market implies +134.0%/yr vs model +15.0% · above model

Aspire Biopharma Holdings, Inc.

Deeply overvalued

Premium +76% Return to IV: -43.2%

Market implies +0.0%/yr vs model +15.0% · below model

ASSEMBLY BIOSCIENCES, INC.

Discount 29% Return to IV: +41.2%

Market implies -5.2%/yr vs model +50.0% · below model

Ascendis Pharma A/S

Assertio Holdings, Inc.

Deeply overvalued

Premium +57% Return to IV: -36.4%

Market implies 0.0%/yr vs model +2.0% · in line

Market implies -7.9%/yr vs model +33.1% · below model

AtaiBeckley Inc.

Market implies +63.5%/yr vs model +50.0% · above model

Alphatec Holdings, Inc.

Deeply undervalued

Discount 69% Return to IV: +227.6%

Market implies -24.0%/yr vs model +33.1% · below model

ALTERITY THERAPEUTICS LTD

Actinium Pharmaceuticals, Inc.

Market implies +88.8%/yr vs model +2.0% · above model

ATOSSA THERAPEUTICS, INC.

Deeply undervalued

Discount 55% Return to IV: +124.0%

Market implies -23.8%/yr vs model +10.7% · below model

Atara Biotherapeutics, Inc.

Premium +0% Return to IV: -0.3%

Market implies -2.6%/yr vs model +15.0% · below model

Deeply overvalued

Premium +61% Return to IV: -37.7%

Market implies +1.5%/yr vs model +18.2% · below model